Benitec Biopharma (BNTC) Competitors $12.56 -0.15 (-1.18%) Closing price 04:00 PM EasternExtended Trading$12.55 -0.01 (-0.08%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BNTC vs. AVDL, CVAC, CALT, PAHC, NTLA, AMPH, XERS, COLL, SNDX, and PHVSShould you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Avadel Pharmaceuticals (AVDL), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Intellia Therapeutics (NTLA), Amphastar Pharmaceuticals (AMPH), Xeris Biopharma (XERS), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Benitec Biopharma vs. Its Competitors Avadel Pharmaceuticals CureVac Calliditas Therapeutics AB (publ) Phibro Animal Health Intellia Therapeutics Amphastar Pharmaceuticals Xeris Biopharma Collegium Pharmaceutical Syndax Pharmaceuticals Pharvaris Benitec Biopharma (NASDAQ:BNTC) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk. Which has higher valuation & earnings, BNTC or AVDL? Benitec Biopharma has higher earnings, but lower revenue than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBenitec Biopharma$80K4,121.25-$21.75M-$1.51-8.32Avadel Pharmaceuticals$169.12M7.87-$48.83M-$0.03-456.67 Is BNTC or AVDL more profitable? Benitec Biopharma has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -1.32%. Avadel Pharmaceuticals' return on equity of -3.73% beat Benitec Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Benitec BiopharmaN/A -38.26% -35.71% Avadel Pharmaceuticals -1.32%-3.73%-1.73% Which has more risk and volatility, BNTC or AVDL? Benitec Biopharma has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Does the media favor BNTC or AVDL? In the previous week, Avadel Pharmaceuticals had 1 more articles in the media than Benitec Biopharma. MarketBeat recorded 4 mentions for Avadel Pharmaceuticals and 3 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.76 beat Avadel Pharmaceuticals' score of 0.17 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Avadel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate BNTC or AVDL? Benitec Biopharma currently has a consensus target price of $26.00, indicating a potential upside of 107.01%. Avadel Pharmaceuticals has a consensus target price of $18.67, indicating a potential upside of 36.25%. Given Benitec Biopharma's higher probable upside, research analysts plainly believe Benitec Biopharma is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Do insiders and institutionals have more ownership in BNTC or AVDL? 52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by company insiders. Comparatively, 5.2% of Avadel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryAvadel Pharmaceuticals beats Benitec Biopharma on 9 of the 16 factors compared between the two stocks. Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNTC vs. The Competition Export to ExcelMetricBenitec BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$333.64M$3.11B$5.73B$9.80BDividend YieldN/A2.22%4.54%4.08%P/E Ratio-8.3220.3530.7425.12Price / Sales4,121.25319.45441.05108.85Price / CashN/A42.8237.3459.16Price / Book2.687.698.886.24Net Income-$21.75M-$54.72M$3.26B$265.56M7 Day Performance1.37%2.03%1.73%0.90%1 Month Performance13.77%4.10%3.54%1.88%1 Year Performance39.56%8.23%28.63%20.09% Benitec Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNTCBenitec Biopharma1.7004 of 5 stars$12.56-1.2%$26.00+107.0%+44.3%$333.64M$80K-8.3220AVDLAvadel Pharmaceuticals2.6145 of 5 stars$12.79+0.3%$18.67+45.9%-15.4%$1.23B$169.12M-426.3370CVACCureVac4.6023 of 5 stars$5.43-0.2%$6.83+25.8%+68.2%$1.22B$579.18M5.90880Earnings ReportUpcoming EarningsShort Interest ↓CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health3.4907 of 5 stars$28.54+1.6%$24.40-14.5%+73.1%$1.14B$1.02B36.591,940Positive NewsNTLAIntellia Therapeutics4.4464 of 5 stars$10.74-0.5%$30.68+185.7%-52.6%$1.12B$57.88M-2.29600AMPHAmphastar Pharmaceuticals3.3488 of 5 stars$27.36+14.9%$30.00+9.6%-33.8%$1.11B$731.97M10.252,028High Trading VolumeXERSXeris Biopharma3.4027 of 5 stars$7.20+5.3%$6.25-13.2%+173.6%$1.10B$203.07M-34.28290COLLCollegium Pharmaceutical2.9274 of 5 stars$36.14+3.5%$42.33+17.1%+8.3%$1.10B$631.45M34.75210Insider TradeSNDXSyndax Pharmaceuticals4.0378 of 5 stars$12.51+0.2%$36.91+195.0%-20.4%$1.08B$23.68M-3.22110News CoverageInsider TradePHVSPharvaris2.7415 of 5 stars$20.84+3.6%$36.20+73.7%+18.2%$1.05BN/A-6.9230News CoverageEarnings ReportShort Interest ↓Analyst Revision Related Companies and Tools Related Companies AVDL Alternatives CVAC Alternatives CALT Alternatives PAHC Alternatives NTLA Alternatives AMPH Alternatives XERS Alternatives COLL Alternatives SNDX Alternatives PHVS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BNTC) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access